Core Viewpoint - The article highlights the challenges faced by Guizhou BaiLing's actual controller, Jiang Wei, including a lawsuit amounting to 1.7 billion yuan and an investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which have significantly impacted investor confidence in the company [1][4]. Company Overview - Guizhou BaiLing, known as the "first stock of苗药" (Miao medicine), was founded by Jiang Wei, who has built the company over 30 years and previously enjoyed significant success in the capital market [1][11]. - The company has faced increasing scrutiny and negative sentiment from investors over the past few years, leading to a decline in stock performance and overall investor confidence [3][5]. Recent Developments - On December 3, the company announced that Jiang Wei received a notice from the CSRC regarding an investigation into insider trading and other violations, which the company stated would not affect its daily operations [4]. - Following the announcement, Guizhou BaiLing's stock price fell significantly, with a maximum intraday drop of over 7%, closing at 5.22 yuan per share, a decrease of 6.28%, leading the A-share traditional Chinese medicine sector [5]. Legal Issues - Jiang Wei is currently facing a lawsuit from Huachuang Securities for a total of 1.7 billion yuan related to a financial rescue plan and stock pledge disputes, which has been accepted by a local court [6][10]. - The lawsuit stems from a financial arrangement where Huachuang Securities provided 1.4 billion yuan in funding to Jiang Wei through stock transfers and additional loans, which have not been repaid as agreed [6]. Financial Performance - Guizhou BaiLing's financial performance has been declining, with a record revenue of 4.263 billion yuan in 2023 but a net loss of 415 million yuan, marking the first loss since its listing [13]. - The company reported a revenue of 2.102 billion yuan and a net profit of 56.81 million yuan in the first three quarters of 2023, representing year-on-year declines of 24.28% and 35.60%, respectively [13]. Historical Context - Jiang Wei's wealth peaked in 2017 at 16.5 billion yuan, making him the richest person in Guizhou, but he has since fallen off the list due to the decline in the company's stock price and his financial troubles [12][15]. - The company has faced continuous scrutiny from regulatory bodies, receiving inquiry letters from the exchange for over ten consecutive years, which is uncommon in the A-share market [14].

Key Points - Company Grinda plans to invest 80 million yuan to subscribe for 1.91% of Muxi's initial public offering shares [1] - Fuyong Technology clarifies that its products do not possess AI capabilities [1] - Bohui Paper Industry intends to invest 1.7 billion yuan to establish a project with an annual production capacity of 320,000 tons of chemical pulp [1] - Jinggong Technology has won the bid for the Wuhan Qingshan high-performance carbon fiber production base project [1] - Yonghe Intelligent Control plans to transfer 100% equity and debt of its wholly-owned subsidiary Chengdu Shanshui [2] - Zhigang Home plans to repurchase shares with an investment of 80 million to 110 million yuan [2] - Meikailong's shareholder Hangzhou Haoyue intends to reduce its holdings by no more than 131 million shares [2] - International Medical plans to raise no more than 1.008 billion yuan through a private placement [2] - Guizhou Bailin's actual controller Jiang Wei has received a notice of investigation from the Securities Regulatory Commission [2]

针对此次调查，在12月3日晚贵州百灵微信号发布的《姜伟董事长致贵州百灵全体同事的一封信》中， 姜伟表示："最近几年，贵州百灵和我个人非议不断。2024年上半年，公司股票被ST处理；2025年公司 完成摘帽，各方面发展重回正轨，我作为公司控股股东却又遭到华创证券无理巨额起诉；今天，我个人 又受到中国证监会的立案调查。这一切都让我有一个强烈的感觉：似乎矛头开始转向了我个人。" 中国经济网北京12月4日讯 12月4日，贵州百灵（002424）企业集团制药股份有限公司（以下简称"贵州 百灵）披露公告，公司实际控制人姜伟近日收到中国证监会下发的《立案告知书》，姜伟因涉嫌内幕交 易、信息披露违法、违反限制性规定转让股票被立案调查。 ...

Core Viewpoint - Guizhou BaiLing's stock price dropped significantly following the announcement of its actual controller, Jiang Wei, being investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, adding to the company's existing performance challenges [1][2]. Group 1: Investigation and Leadership Impact - Jiang Wei, the core figure of Guizhou BaiLing, is under investigation, which may lead to a leadership vacuum and raise market suspicions about the company's stability, potentially affecting investor confidence and causing stock price declines [3]. - Jiang Wei expressed his commitment to cooperate with the investigation and highlighted ongoing personal and corporate challenges, including a significant lawsuit from Huachuang Securities and the potential for the company's stock to be classified as ST (special treatment) in the first half of 2024 [2]. Group 2: Legal Disputes - A legal dispute with Huachuang Securities involves a claim of 1.761 billion yuan, stemming from a failed rescue cooperation initiated in 2020, where Guizhou BaiLing sought financial support due to high debt levels and stock pledge rates [4]. - Jiang Wei has counter-sued Huachuang Securities, accusing them of failing to exit the agreement as promised and seeking damages for stock price losses due to alleged malicious reporting [5]. Group 3: Financial Performance - Guizhou BaiLing's financial performance has deteriorated, with a reported revenue of 2.102 billion yuan for the first three quarters of the year, a 24.28% decrease year-on-year, and a net profit of 56.81 million yuan, down 35.60% [7]. - The company has only achieved 52.55% of its annual revenue target of 4 billion yuan and less than half of its net profit goal of 120 million yuan, attributing the decline to high reliance on specific product categories and external market pressures [6][7]. Group 4: Strategic Measures - The company is implementing self-rescue measures, including a shift from a large-package marketing model to a direct sales model, and is conducting phase III clinical trials for its diabetes-related product [8].

12月3日晚间，贵州百灵（002424）企业集团制药股份有限公司（002424.SZ，简称：贵州百灵）发布公告，披露公司实际控制人姜伟近日收到 中国证券监督管理委员会（以下简称"证监会"）下发的《立案告知书》。告知书显示，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定 转让股票等行为，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，被证监会正式立案调查。 来源：贵州百灵公告 公告强调，本次立案系对姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影响。 然而，这一声明的市场说服力正面临严峻考验。姜伟作为贵州百灵的实际控制人、董事长、法定代表人，并且在原董事会秘书辞职后长期代行 董事会秘书职责（根据公司2024年12月13日公告，原董秘辞职后，董事长姜伟自2024年12月13日起代行董秘职责），其个人行为的合法合规性 与上市公司的治理质量、信息披露质量紧密相连。尤其是在"信息披露违法"这一指控上，实控人个人行为与上市公司法定披露义务之间是否存 在关联，是后续调查的关键，也是市场疑虑的焦点。 此次针对"掌门人"个人的立案，距离贵州百灵自身因涉嫌信息披露违 ...

此外，姜伟同样提到，最近几年，贵州百灵和其个人非议不断。"2024年上半年，公司股票被ST处理；2025年公司完 成摘帽，各方面发展重回正轨，我作为公司控股股东却又遭到华创证券无理巨额起诉；今天，我个人又受到中国证监 会的立案调查。这一切都让我有一个强烈的感觉：似乎矛头开始转向了我个人。"。 全员信中提到，目前，贵州百灵一切运营井然有序，发展态势稳健。 近日，贵州百灵企业集团制药股份有限公司（以下简称"公司"）收到公司实际控制人姜伟的通知，其于近日收到中国 证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字03720252005号）。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。 公告表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及 子公司生产经营活动产生影响。立案调查期间，姜伟将积极配合中国证监会的立案调查工作。公司将持续关注上述事 项的进展情况，并严格按照相关法律法规及监管要求及时履行信息披露义务。 ...

贵州百灵企业集团制药股份有限公司（以下简称"公司"）收到公司实际控制人姜伟先生的通知，其于近 日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字 03720252005号）。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转让股 票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其 进行立案。 本次立案系对公司实际控制人姜伟先生个人的调查，与公司日常经营管理和业务活动无关，不会对上市 公司及子公司生产经营活动产生影响。立案调查期间，姜伟先生将积极配合中国证监会的立案调查工 作。公司将持续关注上述事项的进展情况，并严格按照相关法律法规及监管要求及时履行信息披露义 务。 公司所有信息均以在指定信息披露媒体披露的信息为准，敬请广大投资者理性投资，注意投资风险。 特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002424 证券简称：贵州百灵 公告编号：2025-047 贵州百灵企业集团制药股份有限 公司关于实际控制人收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证公告内容真 ...

Market Overview - On December 4, A-shares showed mixed performance with the Shanghai Composite Index down 0.06% at 3875 points, while the Shenzhen Component Index rose by 0.4% and the ChiNext Index increased by 1.01% [1][2] - The total trading volume in the Shanghai and Shenzhen markets was 1.55 trillion yuan, a decrease of 121 billion yuan compared to the previous trading day [1] Sector Performance - The robotics sector experienced a surge, with stocks like Hengerdai, Haichang New Materials, and Huawu Co. hitting the 20% daily limit up [4][5] - The commercial aerospace concept also strengthened, with multiple stocks including Dahua Intelligent and Sichuan Jinding reaching their daily limit [7] - The semiconductor sector saw gains, with Hongwei Technology rising over 9% [9][10] - The film and cinema sector rallied, with Bona Film Group increasing by over 9% [11][12] - The Hainan sector faced declines, with stocks like Roniu Mountain and Hainan Ruize hitting the daily limit down [13][14] - The liquor sector weakened, with companies like Shede Liquor and Luzhou Laojiao dropping over 3% [15][16] Key Stock Movements - Notable gainers in the robotics sector included: - Hengerdai: +20.01% at 58.60 yuan - Haichang New Materials: +19.99% at 25.57 yuan - Huawu Co.: +19.96% at 11.24 yuan [5][8] - In the commercial aerospace sector, Haichang New Materials and Huawu Co. also saw significant increases [7] - The semiconductor sector's notable performers included: - Hongwei Technology: +9.55% at 28.00 yuan - Zhongke Blue News: +8.90% at 158.53 yuan [10] - In the film sector, Bona Film Group rose by 9.06% to 8.55 yuan [12] Future Outlook - UBS China strategists expect the A-share market to continue its upward trend, projecting an increase in earnings growth to 8% in 2026, up from 6% in 2025 [19]

中国经济网北京12月4日讯 贵州百灵(002424.SZ)昨晚发布关于实际控制人收到中国证券监督管理 委员会立案告知书的公告。 贵州百灵收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监立案字03720252005号）。按照该告知书，姜伟因涉 嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》《中华人民共 和国行政处罚法》等法律法规，中国证监会决定对其进行立案。 贵州百灵表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无 关，不会对上市公司及子公司生产经营活动产生影响。立案调查期间，姜伟将积极配合中国证监会的立 案调查工作。公司将持续关注上述事项的进展情况，并严格按照相关法律法规及监管要求及时履行信息 披露义务。 中国经济网记者致电贵州百灵了解详情，贵州百灵方面回应称，关于实控人被立案一事，公司昨天 才收到立案告知书，具体情况还不太清楚，目前正在配合调查。 （责任编辑：徐自立） 每日经济新闻报道《贵州百灵实控人突遭立案调查 自称与华创证券纠纷矛头转向个人》显示，姜 伟于12月3日晚 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇12月4日｜贵州百灵（维权）(002424.SZ)盘中跌8.62%至5.09元，股价创6月30日以来逾5个月新低。贵州百灵公告，公司收到公司实际控制人姜伟先生 的通知，其于近日收到中国证券监督管理委员会下发的《立案告知书》。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转让股 票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。本次立案系对公司实际控制人姜伟先生个 人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影响。(格隆汇) ...